Development and Market Launch of Virus-Control Products Based on Advanced Ozone Equipment
First written in FY2020-Q3. 4 of 7 entries say "Reframed", first in FY2022. Latest entry: FY2024.
Puequ moved to the "Worse" side of this theme in 2022.
The whole theme swung hardest in 2024: 1 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2024ReframedAnnual report
「In the environmental and energy business, the Group is conducting research and development on hydroponic cultivation equipment. Total research and development expenses for this business in the fiscal year were ¥27 million.」
The research and development theme has shifted from ozone and microbubble technology to hydroponic cultivation equipment, and annual research and development expenses of ¥27 million are disclosed. - FY2023ReframedAnnual report
「In the environmental and energy business, the Company is conducting research and development on ozone gas generators with the aim of commercializing microbubble technology. Total research and development expenses for this business in the fiscal year were ¥33 million.」
Research and development aimed at commercializing microbubble technology is described as focusing on ozone gas generators rather than the nanobubble generators cited previously, and annual research and development expenses of ¥33 million are disclosed. - FY2023-Q3RestatedAnnual report
「In the environmental and energy business, the Company is conducting research and development on nanobubble generators with the aim of commercializing microbubble technology. Group-wide research and development expenditure for the nine-month period of the fiscal year under review was ¥21 million.」
Research and development in microbubble technology, expanded from ozone equipment to nanobubble generators, is continuing, and research and development expenditure of ¥21 million for the nine-month period is disclosed. - FY2023-Q2ReframedAnnual report
「In the environmental and energy business, the Company is conducting research and development on nanobubble generators with the aim of commercializing microbubble technology. Group-wide research and development expenditure for the six-month period of the fiscal year under review was ¥10 million.」
The target of research and development in microbubble technology is now described as nanobubble generators, rather than the ozone gas generators cited previously, and research and development expenditure of ¥10 million for the period is disclosed. - FY2022ReframedAnnual report
「In the environmental and energy business, the Company is conducting research and development on ozone gas generators with the aim of commercializing microbubble technology. Total research and development expenses for this business in the fiscal year were ¥9 million.」
The ozone equipment development theme is described as research and development aimed at commercializing microbubble technology, rather than the market launch of a virus-control product, and research and development expenses of ¥9 million for the fiscal year are disclosed. - FY2021-Q3AdvancedAnnual report
「While focusing on promoting orders for the landscape-conscious Sea Wall coastal barrier, the Group has continued work toward developing ozone equipment through joint research with Tohoku University.」
The Company specifically indicates that its existing development policy of advancing and launching ozone equipment remains under joint research with Tohoku University, and that development efforts are continuing. - FY2020-Q3First statedAnnual report
「The Company decided to accelerate technological development and aim to develop and launch a virus-control product with further advances in the safety and functionality of its existing ozone equipment, taking into consideration a possible second or third wave of coronavirus infections and the emergence of new viruses.」
The Company has outlined, for the first time, a policy of developing and launching products that enhance the safety and functionality of its existing ozone equipment in anticipation of future outbreaks and new viruses.